OTR Acquisition Corp.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1395 Brickell Avenue Miami FL United States of America 33131
- IPO Date
- Dec 15, 2020
- CIK
- 0001821318
- Website
- otracquisition.com
- Similar Companies
- Business
- Since May 19, 2022, OTR Acquisition Corp. completed a reverse merger with Comera Life Sciences Holdings, Inc., establishing Comera Life Sciences as the operating entity. The combined company now focuses on the biotechnology sector, specifically advancing bio-innovative biologic medicines. Comera Life Sciences develops proprietary subcutaneous (SQ) therapeutics, utilizing its distinctive SQore™ formulation platform to convert traditionally intravenous (IV) administered essential biologic treatments into self-injectable forms. This approach aims to enhance patient access, convenience, and safety, fostering greater independence from institutional care and potentially lowering healthcare costs. The company also engages in research collaborations with other pharmaceutical and biotechnology firms, applying its platform to their biologic medicines. Following the merger, Comera Life Sciences began trading on the Nasdaq Capital Market under the ticker symbol CMRA. The company, which originated in 2022, is headquartered in Woburn, Massachusetts, and has expanded its research and development facilities.
Comera Life Sciences Debuts as Publicly Traded Company Focused on Transforming Biologics
Why Is OTR Acquisition (OTRA) Stock Up Today?
Comera Life Sciences Announces Research Collaboration with Top 10 Pharmaceutical Company to Develop Subcutaneous Formulation
Comera Life Sciences to Present at 18th Annual PEGS Boston Conference & Expo
Comera Life Sciences and Intas Pharmaceuticals Announce Research Collaboration
Comera Life Sciences and OTR Acquisition Corp. Announce Effectiveness of Registration Statement for Proposed Business Combination
OTR Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination
OTR Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination
Comera Life Sciences to Become Publicly Traded via Business Combination with OTR Acquisition Corp.